<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>PENTOXIFYLLINE</b></p>

<p><b>From the French ANSM drug interactions document of September 2016, p. 174</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>PENTOXIFYLLINE</b></p>

<p><b>RxNorm: 8013</b></p>

<p><b>ATC: C04AD03</b></p></td>
<td valign="top"><p><b>NON STEROIDAL ANTI-INFLAMMATORY DRUGS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>M01A-002</b></p></td>
<td valign="top"><p>Increase of the risk of hemorrhage</p>

</td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>PENTOXIFYLLINE</b></p>

<p><b>RxNorm: 8013</b></p>

<p><b>ATC: C04AD03</b></p></td>
<td valign="top"><p><b>VITAMIN K ANTAGONISTS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>B01AA-001</b></p></td>
<td valign="top"><p>Increase of the risk of hemorrhage</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped.</p></td>
</tr>

<tr>
<td valign="top"><p><b>PENTOXIFYLLINE</b></p>

<p><b>RxNorm: 8013</b></p>

<p><b>ATC: C04AD03</b></p></td>
<td valign="top"><p><b>THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>R03DA</b></p></td>
<td valign="top"><p>Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped<b>.</b></p></td>
</tr>

</tbody>
</table>

